PRISM BioLab Co., Ltd.

Founded in Fujisawa, Japan, PRISM BioLab Co. , Ltd. specializes in innovative drug discovery, utilizing proprietary PepMetics® Technology to convert challenging therapeutic targets into viable options for pharmaceutical development. PRISM BioLab Co.

, Ltd. focuses on drug discovery through its proprietary PepMetics® Technology, which targets previously undruggable areas. Established in 2006 in Fujisawa-shi, Japan, the company has successfully completed 8 deals. It recently raised JPY 1.

8 billion in a SERIES C funding round on July 2, 2024, primarily from Santec Holdings Corporation, bringing its total amount raised to JPY 1. 8 billion. The company is headquartered in Fujisawa, Japan. PRISM BioLab specializes in innovative drug discovery through its proprietary PepMetics® Technology, converting previously undruggable targets into therapeutic options.

Its core offerings include PepMetics Molecules, which mimic α-helix or β-turn peptides, utilizing stable scaffolds to enhance drug efficacy. The extensive PepMetics Real Library contains over 20,000 compounds for screening diverse amino acid sequences, targeting challenging pharmacological areas, especially intrinsically disordered proteins. The products primarily serve pharmaceutical companies and research institutions focused on drug development in North America, Europe, and Asia. PRISM BioLab generates revenue through collaborations and partnerships with pharmaceutical and biotechnology firms.

The company typically engages in B2B transactions, offering its PepMetics® Technology under strategic drug discovery agreements. Revenue is generated from project-based partnerships, which may involve upfront payments, milestone payments linked to development phases, and royalties on successful drug discoveries. Pricing structures for PepMetics® products vary by collaboration scope, supporting long-term client relationships and the successful commercialization of drug candidates. In July 2024, PRISM BioLab Co.

, Ltd. successfully raised JPY 1. 8 billion in an IPO, selling 4 million shares at JPY 450 per share on the Tokyo Stock Exchange Growth Section, valuing the company at JPY 15. 91 billion.

Looking ahead, PRISM BioLab plans to expand its product offerings and enter new geographic markets, particularly targeting increased presence in Europe and North America by 2025. The recent funding will support these initiatives and enhance the development of new products within their PepMetics® lineup.